Rick Doblin on the FDA's MDMA Decision and the Future of Psychedelic Therapy
Timely insights from Rick Doblin on the FDA's decision on MDMA and its impact on psychedelic research and therapy in 2025.
Webinar description
MAPS Canada Board members Rielle Capler and Reverdi Darda invited Rick Doblin (founder of MAPS) to join them for a conversation at the beginning of 2025. They spoke about: Steps being taken to address the FDA’s feedback and the issues that were raised; the impact of the FDA's MDMA decision on Lykos Therapeutics and MAPS; how the new political administration in the USA might influence the future of MDMA approval and psychedelic research; what impact the FDA's decision and the current U.S. political climate might have on psychedelic research and therapy in Canada.
-
-
Description
-
Video Recording Rick Doblin on FDA's MDMA Decision
-
.png)
About this course
- Free
- 1.5 hours of video content
Start your learning journey
Additional products
-
School of Psychedelics Annual Membership
Bundle • 27 learning productsGet unlimited access to all our premium content for a full year. Enjoy exclusive resources, new releases, and priority support. Learn anytime, anywhere, and advance your skills with our comprehensive library. Join today and start your journey!
$500
-
Psychedelics in Canada: Past, Present and Future
Bundle • 8 learning productsExperience the full spectrum of psychedelic knowledge with our complete seminar series. These seven insightful courses cover everything from the historical roots to the modern applications of psychedelics.
$250
-
Cannabis and Psychedelics: From Conceptualization to Care in Canada
Bundle • 8 learning productsThis course considers the similarities and differences between cannabis and psychedelics, exploring whether cannabis is a psychedelic substance, why that matters, and to whom.
$150
